Ela Delikgöz Soykut

Ela Delikgöz Soykut

Auto-generated profile, based on publicly available information

Ela Delikgöz Soykut

Samsun Eğitim ve Araştırma Hastanesi

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2013 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
FHFernanda G. Herrera
Fernanda G. Herrera
SCSharon Callaway
Sharon Callaway
EDEla Delikgoz-Soykut
Ela Delikgoz-Soykut
MCMehtap Coskun
Mehtap Coskun
LPLaetitia Porta
Laetitia Porta
MOMahmut Ozsahin
Mahmut Ozsahin
Whole pelvis intensity modulated radiotherapy (IMRT) is increasingly being used to treat cervical cancer aiming to reduce side effects. Encouraged by this, some groups have proposed the use of simultaneous integrated boost (SIB) to target the tumor, either to get a higher tumoricidal effect or to replace brachytherapy. Nevertheless, physiological organ movement and rapid tumor regression throughout treatment might substantially reduce any benefit of this approach.

10 October 2021 in Journal of Medical Imaging and Radiation Oncology
Verified
Journal Article
Closed access
PDF file
ESEla Delikgoz Soykut
Ela Delikgoz Soykut
YKYasemin Kemal
Yasemin Kemal
CKCengiz Karacin
Cengiz Karacin
OKOzden Karaoglanoglu
Ozden Karaoglanoglu
MKMumin Kurt
Mumin Kurt
SASuheyla Aytac Arslan
Suheyla Aytac Arslan

1 January 2013 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ESEla Delikgoz Soykut
Ela Delikgoz Soykut
EOEsat Mahmut Ozsahin
Esat Mahmut Ozsahin
YGYildiz Guney
Yildiz Guney
SASuheyla Aytac Arslan
Suheyla Aytac Arslan
OOOzlem Derinalp Or
Ozlem Derinalp Or
PTPelagia G. Tsoutsou
Pelagia G. Tsoutsou
The use of PET/CT in radiotherapy planning: contribution of deformable registration


25 July 2023 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
ESEla Delikgoz Soykut
Ela Delikgoz Soykut
EOEylem Odabasi
Eylem Odabasi
NSNilgun Sahin
Nilgun Sahin
HTHatice Tataroglu
Hatice Tataroglu
ABAhmet Baran
Ahmet Baran
YGYildiz Guney
Yildiz Guney
Background: Despite the radical treatments applied, recurrence is encountered in the majority of high-grade gliomas (HGG). There is no standard treatment when recurrence is detected, but stereotactic radiotherapy (SRT) is a preferable alternative. The aim of this retrospective study is to evaluate the efficacy of SRT for recurrent HGG, and to investigate the factors that affect survival. Materials and methods: From 2013 to 2021, a total of 59 patients with 64 lesions were re-irradiated in a single center with the CyberKnife Robotic Radiosurgery System. The primary endpoints of the study were overall survival (OS), progression free survival (PFS) and local control rates (LCR). Results: The median time to first recurrence was 13 (4–85) months. SRT was performed as a median prescription dose of 30 Gy (range 15–30), with a median of 5 fractions (1–5). The median follow-up time was 4 months (range 1–57). The median OS was 8 (95% CI: 4.66-11.33) months. Age, grade 3, tumor size were associated with better survival. The median PFS was 5 [95% confidence interval (CI): 3.39–6.60] months. Age, grade 3 and time to recurrence > 9 months were associated with improved PFS. Grade 3 gliomas (p = 0.027), size of tumor < 2 cm (p = 0.008) remained independent prognostic factors for OS in multivariate analysis. Conclusion: SRT is a viable treatment modality with significant survival contribution. Since it may have a favorable prognostic effect on survival in patients with tumor size < 2 cm, we recommend early diagnosis of recurrence and a decision to re-irradiate a smaller tumor during follow-up. Background: Despite the radical treatments applied, recurrence is encountered in the majority of high-grade gliomas (HGG). There is no standard treatment when recurrence is detected, but stereotactic radiotherapy (SRT) is a preferable alternative. The aim of this retrospective study is to evaluate the efficacy of SRT for recurrent HGG, and to investigate the factors that affect survival. Materials and methods: From 2013 to 2021, a total of 59 patients with 64 lesions were re-irradiated in a single center with the CyberKnife Robotic Radiosurgery System. The primary endpoints of the study were overall survival (OS), progression free survival (PFS) and local control rates (LCR). Results: The median time to first recurrence was 13 (4–85) months. SRT was performed as a median prescription dose of 30 Gy (range 15–30), with a median of 5 fractions (1–5). The median follow-up time was 4 months (range 1–57). The median OS was 8 (95% CI: 4.66-11.33) months. Age, grade 3, tumor size were associated with better survival. The median PFS was 5 [95% confidence interval (CI): 3.39–6.60] months. Age, grade 3 and time to recurrence > 9 months were associated with improved PFS. Grade 3 gliomas (p = 0.027), size of tumor < 2 cm (p = 0.008) remained independent prognostic factors for OS in multivariate analysis. Conclusion: SRT is a viable treatment modality with significant survival contribution. Since it may have a favorable prognostic effect on survival in patients with tumor size < 2 cm, we recommend early diagnosis of recurrence and a decision to re-irradiate a smaller tumor during follow-up.

1 January 2013 in Turkiye Klinikleri Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
YGYıldız Yükselen Güney
Yıldız Yükselen Güney
NÖNaciye Işık Özşeker
Naciye Işık Özşeker
GIGonca Altinişik İnan
Gonca Altinişik İnan
ESEla Deli̇kgöz Soykut
Ela Deli̇kgöz Soykut
SASüheyla Aytaç Arslan
Süheyla Aytaç Arslan
EKEbru Karakaya
Ebru Karakaya